摘要:
The invention relates to a method for the in vitro distinction between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions. Said method comprises the following steps: a) sample RNA is isolated from a biological sample; b) the sample RNA and/or at least one DNA which represents a gene activity that is specific for distinguishing between SIRS and sepsis and/or a specific gene or gene fragment, is marked with a detectable marker; c) the sample RNA is brought in contact with the DNA in hybridization conditions; d) control RNA is brought in contact with at least one DNA in hybridization conditions, said DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis; e) the marking signals of the hybridized sample RNA and control RNA are quantitatively recorded; and f) the quantitative data of the marking signals is compared in order to make a statement as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA.
摘要:
The invention relates to a method for the in vitro diagnosis of a Chlamydia pneumoniae-specific infection. Said method is characterized in that the presence of at least one of the proteins dnaJ and hydrolase/phosphatase homolog and/or derivatives thereof and/or at least one antibody directed against said proteins and/or derivatives thereof is detected in a patient's sample. Also disclosed are a kit for carrying out the in vitro diagnostic method as well as the preventive and therapeutic use of said biomarkers.
摘要:
The present invention relates to the use of polynucleotides with a length of from 2 to 100% of the number of nucleotides of the individual sequences shown in SEQ-ID No. 1 to SEQ-ID No. 69 and/or the gene loci thereof and/or the transcripts thereof for detecting gene activities for distinguishing a condition associated with a local infection from a condition associated with a systemic infection in a patient, using all the sequences shown in SEQ-ID No. 1 to SEQ-ID No. 69; and to a method and a kit for carrying out the method.
摘要:
The present invention relates to control genes, primers, and probes for the normalization of gene expression analysis data from the blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data using control genes, primers, or probes.
摘要:
The invention relates to the use of gene expression profiles obtained in vitro from patient samples for differentiating between the non-infectious and infectious causes of multiple organ failure. The invention also relates to a method for measuring gene expression profiles in vitro and to the use of said gene expression profiles and/or of the probes used therein for screening active substances against the non-infectious and/or infectious causes of multiple organ failure.
摘要:
The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, said protein being 25 %-35 % homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.
摘要:
The invention relates to the use of gene activity markers for the classification of patients suffering from infectious or non-infectious multiple organ failure. The invention especially relates to gene activity markers for classifying patients as 'non-infected without multiple organ failure' or as 'not suffering from multiple organ failure' or as 'suffering from infectious multiple organ failure . The gene activity markers are polynucleotides selected from the group consisting of: SEQ ID I.1, SEQ ID I.2, SEQ ID I.3, SEQ ID I.4, SEQ ID I.5, SEQ ID I.6, SEQ ID I.7, SEQ ID I.8 and SEQ ID I.9 or partial sequences thereof.
摘要:
The present invention relates to control genes, primers, and probes for the normalization of gene expression analysis data from the blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data using control genes, primers, or probes.
摘要:
The present invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for detecting any postoperative tissue incompatibility reactions following a liver transplantation, wherein in patients the gene activity of a plurality of specific genes relevant to a liver transplantation is determined in a patient sample, and the specific genes and/or gene fragments for monitoring of postoperative states are selected from the group consisting of: SEQ-ID No. 1 to SEQ-ID No. 532, these preferably being subdivided into several clusters.
摘要:
The invention relates to a method for in vitro recognition of SIRS, sepsis and/or sepsis-like conditions. Said method enables the degree of severity to be evaluated and/or assessment during the course of therapy of sepsis and serious infections, especially sepsis-like systemic infections. The invention also relates to the use of recombinant or synthetically produced nucleic acid sequences or peptide sequences derived therefrom as a calibrator in sepsis-assays and/or in order to assess the effect and toxicity in active substance screening and/or in the production of therapeutics in order to prevent and treat SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.